uPAR and HER2 genes are usually co-amplified in individual breast cancer cells from blood and tissues

Breast Care

Volumn 3, Issue SUPPL. 2, 2008, Pages 16-19

  Uhr, Jonathan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BREAST CANCER; CANCER CELL; CLINICAL ARTICLE; CONFERENCE PAPER; EPITHELIUM CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; ONCOGENE NEU; PRIORITY JOURNAL; UPAR GENE;

EID: 56249147476     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000151738     Document Type: Conference Paper

References (21)

1. Sidenius N, Blasi F: The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis 2003;22:205-222.
2. Romer J, Nielsen BS, Ploug M: The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-2376.
3. Grondahl-Hansen J, Peters HA, van Putten WL, Pappot H, Ronne E, Dano K, Klijn JG, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-1087.
4. de Witte JH, Foekens JA, Brunner N, Heuvel JJ, van Tienoven T: Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001;85:85-92.
5. Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K: Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumour cells. Int J Cancer 2003;107:903-909.
6. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumour tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-1141.
7. Duggan C, Maquire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
8. Kotzsch M, Farthmann J, Meye A, Fuessel S, Baretton G, Tjan-Heijnen VC: Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer 2005;41:2760-2768.
9. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D: Cathepsin B, plasminogen-activator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-4161.
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
13. Yeon CH, Pegram MD: Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005;23:391-409.
14. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Summans WF, Pusztai L, Hortobagyi GN: Targeted therapy in breast cancer: The HER2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-182.
16. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen L, Fehm T, Tucker TF, Lane N, Wang J, Uhr J: Circulating tumour cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-8162.
17. Fehm T, Morrison L, Saboorian H, Hynan L, Tucker T, Uhr J: Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumours. Breast Cancer Res Treat 2002;75:227-239.
18. Fehm T, Sagalowsky AI, Clifford E, Beitsch PD, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002;8:2073-2084.
19. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frankel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen L, Lane N, Wang J, Uhr J: uPAR and HER2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006;103:17361-17365.
20. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen L, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J: HER2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;101:9393-9398.
21. Han B, Nakamura M, Mori I, Nakamura Y, Kakuda K: Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep 2005;14:105-112.